

Diane F Jelinek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11962439/publications.pdf>

Version: 2024-02-01

120
papers

8,168
citations

41323

49
h-index

46771

89
g-index

120
all docs

120
docs citations

120
times ranked

8373
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 2582-2590.	13.9	740
2	Ibrutinib vs Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2019, 381, 432-443.	13.9	545
3	Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. <i>Blood</i> , 2004, 103, 689-694.	0.6	474
4	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. <i>Blood</i> , 2008, 111, 785-789.	0.6	355
5	Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997. <i>Journal of Clinical Oncology</i> , 2007, 25, 799-804.	0.8	320
6	Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. <i>Blood</i> , 2007, 109, 405-411.	0.6	278
7	Regulated Expression of BAFF-Binding Receptors during Human B Cell Differentiation. <i>Journal of Immunology</i> , 2007, 179, 7276-7286.	0.4	236
8	Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, 4634-4641.	0.8	223
9	Expression of BlyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. <i>Blood</i> , 2004, 104, 2247-2253.	0.6	216
10	IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. <i>Blood</i> , 2004, 103, 2308-2315.	0.6	215
11	Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. <i>Blood</i> , 2002, 100, 2973-2979.	0.6	213
12	Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003, 121, 287-295.	1.2	198
13	Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 115, 854-861.	1.2	179
14	Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 3808-3814.	0.8	161
15	CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin's Lymphoma Predicts Patient Outcome. <i>Journal of Clinical Oncology</i> , 2001, 19, 720-726.	0.8	153
16	CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. <i>British Journal of Haematology</i> , 2008, 140, 537-546.	1.2	152
17	Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2002, 99, 67-74.	0.6	149
18	Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 363-370.	2.0	147

#	ARTICLE	IF	CITATIONS
19	LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. <i>Blood</i> , 2010, 116, 2975-2983.	0.6	136
20	Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 3959-3963.	0.8	123
21	Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 2483-2491.	0.8	120
22	Platelet-derived growth factor (PDGF)â€“PDGF receptor interaction activates bone marrowâ€“derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. <i>Blood</i> , 2010, 116, 2984-2993.	0.6	113
23	Identification of a global gene expression signature of B-chronic lymphocytic leukemia. <i>Molecular Cancer Research</i> , 2003, 1, 346-61.	1.5	108
24	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010, 116, 4777-4787.	2.0	107
25	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. <i>Blood</i> , 2009, 113, 4188-4196.	0.6	104
26	A role for BLyS in the activation of innate immune cells. <i>Blood</i> , 2006, 108, 2687-2694.	0.6	101
27	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 615-621.	1.2	101
28	Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. <i>Lancet Haematology</i> , 2014, 1, e74-e84.	2.2	93
29	Long-term outcomes for ibrutinibâ€“rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. <i>Blood</i> , 2022, 140, 112-120.	0.6	93
30	Chronic Lymphocytic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2002, 2002, 193-213.	0.9	86
31	Prognostic importance of T and NKâ€“cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2008, 141, 607-614.	1.2	86
32	Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2006, 24, 983-987.	0.8	85
33	Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. <i>Leukemia and Lymphoma</i> , 2007, 48, 2412-2417.	0.6	85
34	A Structurally Distinct Human Mycoplasma Protein that Generically Blocks Antigen-Antibody Union. <i>Science</i> , 2014, 343, 656-661.	6.0	85
35	Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). <i>Blood</i> , 2013, 121, 4137-4141.	0.6	79
36	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. <i>Cancer</i> , 2015, 121, 2883-2891.	2.0	77

#	ARTICLE	IF	CITATIONS
37	Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 139, 398-404.	1.2	76
38	Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 1844-1849.	0.8	71
39	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. <i>Blood</i> , 2015, 125, 856-859.	0.6	70
40	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. <i>Leukemia and Lymphoma</i> , 2009, 50, 1261-1268.	0.6	69
41	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- κ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	0.6	68
42	Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. <i>Cancer</i> , 2008, 113, 2110-2118.	2.0	67
43	Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. <i>Blood</i> , 2008, 112, 1931-1941.	0.6	64
44	Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. <i>Blood</i> , 2009, 113, 535-537.	0.6	61
45	Multiple myeloma cell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. <i>Oncotarget</i> , 2014, 5, 5686-5699.	0.8	59
46	Divergent Effects of BAFF on Human Memory B Cell Differentiation into Ig-Secreting Cells. <i>Journal of Immunology</i> , 2007, 178, 5612-5622.	0.4	57
47	Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration. <i>Clinical Chemistry</i> , 2016, 62, 243-251.	1.5	57
48	Using Smudge Cells on Routine Blood Smears to Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test. <i>Mayo Clinic Proceedings</i> , 2007, 82, 449-453.	1.4	55
49	Proteomic Detection of Immunoglobulin Light Chain Variable Region Peptides from Amyloidosis Patient Biopsies. <i>Journal of Proteome Research</i> , 2015, 14, 1957-1967.	1.8	50
50	B Lymphocyte Stimulator Regulates Adaptive Immune Responses by Directly Promoting Dendritic Cell Maturation. <i>Journal of Immunology</i> , 2008, 180, 7394-7403.	0.4	49
51	Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). <i>Cancer</i> , 2013, 119, 3788-3796.	2.0	41
52	AML-1A and AML-1B regulation of MIP-1 α expression in multiple myeloma. <i>Blood</i> , 2003, 101, 3778-3783.	0.6	40
53	Human B Lymphocyte Malignancies: Exploitation of BLYS and APRIL and Their Receptors. , 2004, 8, 266-288.		35
54	Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 161-168.	1.0	35

#	ARTICLE	IF	CITATIONS
55	Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2005, 29, 253-262.	0.4	30
56	Induction of Malignant Plasma Cell Proliferation by Eosinophils. <i>PLoS ONE</i> , 2013, 8, e70554.	1.1	29
57	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. <i>Blood</i> , 2019, 134, 33-33.	0.6	29
58	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2017, 23, 5292-5301.	3.2	27
59	<scp>CD</scp>49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 178, 99-105.	1.2	23
60	Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. <i>Journal of Clinical Investigation</i> , 2008, 118, 306-315.	3.9	20
61	Comprehensive Assessment of Potential Multiple Myeloma Immunoglobulin Heavy Chain V-DJ Intraclonal Variation Using Massively Parallel Pyrosequencing. <i>Oncotarget</i> , 2012, 3, 502-513.	0.8	19
62	The Structure of the <i>TNFRSF13C</i> Promoter Enables Differential Expression of BAFF-R during B Cell Ontogeny and Terminal Differentiation. <i>Journal of Immunology</i> , 2010, 185, 1045-1054.	0.4	18
63	Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004, 104, 339-339.	0.6	18
64	No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. <i>Haematologica</i> , 2018, 103, e158-e161.	1.7	16
65	Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 819, 33-39.	1.2	15
66	Quantitative Protein Expression Analysis Of CLL B Cells from Mutated and Unmutated IgVHSubgroups Using Acid-Cleavable Isotope-Coded Affinity Tag Reagents. <i>Journal of Proteome Research</i> , 2005, 4, 1310-1317.	1.8	15
67	Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. <i>Cell Cycle</i> , 2010, 9, 4884-4892.	1.3	15
68	Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007, 31, 1737-1740.	0.4	14
69	Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. <i>European Journal of Haematology</i> , 2013, 91, 504-513.	1.1	14
70	A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. <i>Leukemia Research</i> , 2005, 29, 1009-1018.	0.4	13
71	ZAP-70 Expression Associated with Activation in Normal Human B Cells and B Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004, 104, 2794-2794.	0.6	11
72	Selective Induction of DNA Repair Pathways in Human B Cells Activated by CD4+ T Cells. <i>PLoS ONE</i> , 2010, 5, e15549.	1.1	10

#	ARTICLE	IF	CITATIONS
73	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. <i>Leukemia and Lymphoma</i> , 2015, 56, 3031-3037.	0.6	9
74	Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia. <i>Oncotarget</i> , 2019, 10, 60-75.	0.8	6
75	The Comprehensive Genomic Characterization Of All Commercially and Non-Commercially Available Multiple Myeloma Cell Lines. <i>Blood</i> , 2013, 122, 1914-1914.	0.6	6
76	Response: Cautious interpretation of assessment of AID variant activities using cells with endogenous AID expression. <i>Blood</i> , 2009, 113, 1864-1864.	0.6	5
77	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. <i>Cancer Genetics</i> , 2014, 207, 19-30.	0.2	5
78	Multiplex Immunofluorescence of Bone Marrow Core Biopsies: Visualizing the Bone Marrow Immune Contexture. <i>Journal of Histochemistry and Cytochemistry</i> , 2020, 68, 99-112.	1.3	5
79	T Helper Cell Activation in B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2002, 20, 2904-2905.	0.8	4
80	Alemtuzumab and Rituximab for Therapy of Patients with Early Stage High Risk CLL: Report of a Planned Interim Analysis.. <i>Blood</i> , 2006, 108, 2829-2829.	0.6	4
81	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. <i>Blood</i> , 2013, 122, 4179-4179.	0.6	4
82	Stage-Specific Non-Coding RNA Expression Patterns during In Vitro Human B Cell Differentiation into Antibody Secreting Plasma Cells. <i>Non-coding RNA</i> , 2022, 8, 15.	1.3	3
83	Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain. <i>Experimental Hematology</i> , 2018, 57, 42-49.e1.	0.2	2
84	A rare case of selective Ig λ chain deficiency: Biologic and clinical implications. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1208-1210.e6.	1.5	2
85	Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1487-1487.	0.6	2
86	Somatic Hyperrepair: A Novel Tumor Suppression Mechanism for Germinal Center B Cells.. <i>Blood</i> , 2009, 114, 92-92.	0.6	2
87	Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL,. <i>Blood</i> , 2011, 118, 3899-3899.	0.6	2
88	Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes. <i>Blood</i> , 2013, 122, 4178-4178.	0.6	2
89	Molecular Mechanisms Regulating BAFF and APRIL Receptor Expression in B Cells: Promoter Structure and Epigenetics. <i>Blood</i> , 2008, 112, 4765-4765.	0.6	2
90	Aberrant Regulation of the LEF-1 Locus in Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL): A Possible Role for Epigenetic Regulation.. <i>Blood</i> , 2009, 114, 669-669.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).. Blood, 2007, 110, 2050-2050.	0.6	1
92	Role of Lncrnas in Early Stage Immunoglobulin Heavy Chain Variable Region (IGHV) Unmutated CLL Disease Progression. Blood, 2016, 128, 4364-4364.	0.6	1
93	Leukemic B Cells from CD38 Positive but Not CD38 Negative B-CLL Patients Express Heightened Levels of Cell Cycle Related Genes.. Blood, 2004, 104, 4809-4809.	0.6	1
94	Overexpression of the LEF-1 and TCF4 Transcription Factors in B-CLL: Further Evidence for a Role of the Wnt Signaling Pathway in B-CLL Biology and Leukemogenesis. Blood, 2008, 112, 544-544.	0.6	1
95	Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,. Blood, 2011, 118, 3898-3898.	0.6	1
96	Growth and Survival Signals in Myeloma: Roles for BAFF and APRIL?. Clinical Lymphoma and Myeloma, 2009, 9, S19-S21.	1.4	0
97	Elevated BLyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLyS Polymorphisms.. Blood, 2004, 104, 964-964.	0.6	0
98	BLyS Regulates Human Myeloma Cell IL-6 Expression.. Blood, 2004, 104, 1412-1412.	0.6	0
99	Molecular and Clinical Analysis of a Midwest Cohort of B-CLL Patients Utilizing the Immunoglobulin VH 1-69 Gene.. Blood, 2005, 106, 5016-5016.	0.6	0
100	High Density Oligonucleotide Array CGH Analysis of CLL Reveals Areas of Recurrent Genomic Gain or Loss.. Blood, 2006, 108, 2093-2093.	0.6	0
101	Expression and Functional Analysis of Activation-Induced Deaminase (AID) in Normal Human B Lymphocytes.. Blood, 2006, 108, 934-934.	0.6	0
102	D Gene Usage Predicts Clinical Outcome in Patients with Low Rai Risk Unmutated B-CLL.. Blood, 2006, 108, 2779-2779.	0.6	0
103	The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL).. Blood, 2007, 110, 746-746.	0.6	0
104	Comprehensive Analysis of BAFF Binding Receptor Profiles and Receptor Occupancy in B Cell Chronic Lymphocytic Leukemia: Identification of Discrete Phenotypic Subgroups.. Blood, 2007, 110, 1135-1135.	0.6	0
105	Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.. Blood, 2008, 112, 1707-1707.	0.6	0
106	The Histone Methyltransferase MMSET Regulates Class-Switch Recombination. Blood, 2011, 118, 691-691.	0.6	0
107	CD147 Is a Novel Regulator of Progression and Proliferation of Multiple Myeloma Plasma Cells. Blood, 2011, 118, 470-470.	0.6	0
108	Targeting the BAFF/APRIL Cytokine Network in Multiple Myeloma. , 2013, , 187-202.		0

#	ARTICLE	IF	CITATIONS
109	What Numbers Don't Say: Immunogenetic Evidence Shows That High-Count MBL Resembles Rai 0 CLL While Low-Count MBL Does Not.. Blood, 2012, 120, 2883-2883.	0.6	0
110	Molecular Interrogation of Biclinal Multiple Myeloma for Clonal Relatedness.. Blood, 2012, 120, 2928-2928.	0.6	0
111	Chronic Lymphocytic Leukemia in Young (â% 55 years) Patients: A Comprehensive Analysis of Prognostic Factors and Outcomes.. Blood, 2012, 120, 2901-2901.	0.6	0
112	Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 6	0.6	0
113	Eosinophils in the Bone Marrow Microenvironment: Effects On Malignant Plasma Cell Biology.. Blood, 2012, 120, 2917-2917.	0.6	0
114	Monoclonal Gammopathies of Undetermined Significance and Smoldering Multiple Myeloma. , 2014, , 65-80.		0
115	Monitoring Minimum Residual Disease In Multiple Myeloma Patients By LC-MS/MS. Blood, 2013, 122, 3152-3152.	0.6	0
116	Mass Spectrometry-Based Proteomics Reveals Distinct Immunoglobulin Light Chain Variable Region Usage In Systemic Versus Localized AL Amyloidosis. Blood, 2013, 122, 3142-3142.	0.6	0
117	The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087) Tj ETQq1 1 0.784314 rgBT /Ov	0.6	0
118	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. Blood, 2015, 126, 5263-5263.	0.6	0
119	Reliability of Myeloma Model Systems: KP-6 Is a Novel Hyperdiploid Cell Line. Blood, 2016, 128, 3279-3279.	0.6	0
120	RNA-Seq Based Immunoglobulin Repertoire Analysis of Normal Plasma Cells Generated in an in Vitro B Cell Differentiation System. Blood, 2019, 134, 1051-1051.	0.6	0